<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180737</url>
  </required_header>
  <id_info>
    <org_study_id>Dexmedetomidine sedation</org_study_id>
    <nct_id>NCT02180737</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine for Sedation During Radiological Interventional Procedures</brief_title>
  <acronym>Dexmed</acronym>
  <official_title>Evaluation of Role of Dexmedetomidine as a Sole Agent in Sedation of Cancer Patients Undergoing Radiological Interventional Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the role of dexmedetomidine as a sole agent in sedating patients undergoing
      interventional radiological procedures and measuring its different outcome variables.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of sedation</measure>
    <time_frame>1 hour</time_frame>
    <description>It will be measured and recorded by using the Ramsay sedation score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>verbal analogue scale</measure>
    <time_frame>1 hour</time_frame>
    <description>assessment of pain using VAS score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>24 hours</time_frame>
    <description>assessment of patient satisfaction by 4 point scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Procedural Sedation</condition>
  <arm_group>
    <arm_group_label>Dexmeditomedine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine will be initiated at 0.6 mcg/kg/hr and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmeditomedine</intervention_name>
    <arm_group_label>Dexmeditomedine</arm_group_label>
    <other_name>Dexmedetomidine at 0.6 mcg/kg/hr then 0.2 to 1 mcg/kg/hr.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18-65 years old

          -  ASA physical status of I-II

          -  Expected procedure lasting at least 30 minutes

        Exclusion Criteria:

          -  Unstable cardiac status (life-threatening arrhythmias, abnormal cardiac anatomy,
             significant cardiac dysfunction and third-degree heart block.

          -  An alpha2-agonist or antagonist within 14 days before the scheduled procedure.

          -  patients received an IV opioid within 1 h, or an oral or IM opioid within 4 h of the
             start of study drug administration.

          -  Patients who are allergic to Dexmedetomidine or alpha 2-agonists.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wafaa T Salem, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maie K Helaly, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ghada M Bashandy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayat A Hassan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute-Egypt</name>
      <address>
        <city>Cairo</city>
        <zip>112796</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Hsu YW, Cortinez LI, Robertson KM, Keifer JC, Sum-Ping ST, Moretti EW, Young CC, Wright DR, Macleod DB, Somma J. Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology. 2004 Nov;101(5):1066-76.</citation>
    <PMID>15505441</PMID>
  </results_reference>
  <results_reference>
    <citation>Scher CS, Gitlin MC. Dexmedetomidine and low-dose ketamine provide adequate sedation for awake fibreoptic intubation. Can J Anaesth. 2003 Jun-Jul;50(6):607-10.</citation>
    <PMID>12826556</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2014</study_first_posted>
  <last_update_submitted>April 17, 2016</last_update_submitted>
  <last_update_submitted_qc>April 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Ghada M N Bashandy</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>dexmedetomedine</keyword>
  <keyword>sedation</keyword>
  <keyword>interventional radiology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

